{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:55:17Z","timestamp":1758970517173},"reference-count":48,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,2,6]],"date-time":"2006-02-06T00:00:00Z","timestamp":1139184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2006,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>In September 2004, the manufacturer of rofecoxib announced a voluntary worldwide withdrawal of the drug. The impact of this withdrawal on drug budgets is unclear. This study evaluated average daily doses and costs of rofecoxib and celecoxib and concomitant use of gastroprotective agents (GPAs) in elderly patients with osteoarthritis (OA) or rheumatoid arthritis (RA) in Quebec, prior to the rofecoxib withdrawal.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study used prescription drug and medical service data from the Quebec government health agency administrative database and included coxib users \u226566 years of age with OA or RA who filled \u22653 consecutive rofecoxib or celecoxib prescriptions in 2001\u20132002. Results were adjusted for gastrointestinal risk factors and other patient baseline characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data were analyzed for 11,975 rofecoxib and 12,480 celecoxib users. Mean daily dosages were 20.7 mg for rofecoxib and 231.3 mg for celecoxib. Rofecoxib users consumed a mean \u00b1 SD of 0.95 \u00b1 0.43 pills per day, and celecoxib users took 1.34 \u00b1 0.65 pills per day. Mean \u00b1 SD unadjusted daily acquisition costs were $1.18 \u00b1 $0.53 (Canadian) for rofecoxib and $1.45 \u00b1 $0.74 for celecoxib. After adjusting for patient baseline characteristics, the mean daily acquisition cost for rofecoxib was $0.25 lower than for celecoxib. Rofecoxib users were less likely than celecoxib users to fill a GPA coprescription (odds ratio 0.88; 95% confidence interval 0.81, 0.95). Subgroup analyses yielded comparable results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Celecoxib appears to be a more expensive therapeutic option than rofecoxib due to a relatively higher daily dose and tablet consumption.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.21696","type":"journal-article","created":{"date-parts":[[2006,2,6]],"date-time":"2006-02-06T23:46:52Z","timestamp":1139269612000},"page":"27-34","source":"Crossref","is-referenced-by-count":3,"title":["Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: What is the potential impact of the withdrawal of rofecoxib?"],"prefix":"10.1002","volume":"55","author":[{"given":"Elham","family":"Rahme","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"Hunsche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youssef","family":"Toubouti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Chabot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,2,6]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"646","article-title":"Burden of major musculoskeletal conditions","volume":"81","author":"Woolf AD","year":"2003","journal-title":"Bull World Health Organ"},{"key":"e_1_2_5_3_2","volume-title":"Arthritis in Canada: an ongoing challenge","author":"Health Canada","year":"2003"},{"issue":"1","key":"e_1_2_5_4_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/rheumatology\/41.S1.3","article-title":"The prevalence and burden of arthritis","volume":"41","author":"Reginster JY","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.006031"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P"},{"key":"e_1_2_5_7_2","first-page":"4A","article-title":"An evidence\u2010based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis: The Second Canadian Consensus Conference","volume":"7","author":"Tannenbaum H","year":"2000","journal-title":"Can J Clin Pharmacol"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10148"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.011742"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02065549"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00207-6"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.14.2093"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200004)43:4<917::AID-ANR25>3.0.CO;2-F"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2001.00348.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.21907"},{"key":"e_1_2_5_16_2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1155\/2002\/516092","article-title":"Recommendations for the appropriate use of anti\u2010inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents","volume":"16","author":"Hunt RH","year":"2002","journal-title":"Can J Gastroenterol"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0269-2813.2004.01834.x"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011233432103"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.10.1247"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7365.619"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-7-200310070-00005"},{"key":"e_1_2_5_22_2","first-page":"38","article-title":"Persistence with COX\u20102 inhibitors in managed care: an analysis of claims data","volume":"16","author":"Harley C","year":"2003","journal-title":"Manag Care Interface"},{"issue":"3","key":"e_1_2_5_23_2","first-page":"iii17","article-title":"Persistency of use of COX\u20102\u2010specific inhibitors and non\u2010specific non\u2010steroidal anti\u2010inflammatory drugs (NSAIDs) in Quebec","volume":"42","author":"Moride Y","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.322.7282.344"},{"key":"e_1_2_5_25_2","first-page":"467","article-title":"Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX\u20102 therapy","volume":"29","author":"Wolfe F","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10796"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)00234-H"},{"key":"e_1_2_5_28_2","volume-title":"ICD9.CM Millenium Edition: International Classification of Diseases, Ninth Revision, Clinical Modification","year":"2003"},{"key":"e_1_2_5_29_2","volume-title":"Applied linear statistical models: regression, analysis of variance, and experimental designs","author":"Neter J","year":"1990"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)90100-7"},{"key":"e_1_2_5_31_2","first-page":"869","article-title":"COX\u20102\u2010specific inhibitors: prescribing patterns in a large managed care health system and strategies to minimize costs","volume":"8","author":"Weideman RA","year":"2002","journal-title":"Am J Manag Care"},{"key":"e_1_2_5_32_2","unstructured":"IversenT LevorsenA MavrosP KongSX JonssonB.Use patterns and costs of rofecoxib and celecoxib in the management of arthritis based on national pharmacy data in Norway. Presented at the Annual European Congress of Rheumatology Berlin Germany."},{"key":"e_1_2_5_33_2","volume-title":"CPS: Compendium of Pharmaceuticals and Specialties","author":"Schnell BR","year":"2001"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11121"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/acprof:oso\/9780195108408.001.0001"},{"key":"e_1_2_5_36_2","unstructured":"RahmeE TouboutiY HunscheE ChabotI.Therapy switching and associated costs in patients on selective cox\u20102 inhibitors and nonselective NSAIDs in an elderly population in Quebec Canada. Presented at the Annual European Congress of Rheumatology June 9\u201312 2004 Berlin Germany."},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7365.624"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-004-0813-5"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.01913.x"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11131-7"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-7-200504050-00113"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16299-5"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-3-200502010-00005"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000127578.21885.3E"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17864-7"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.9.978"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.2.181"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528050-00006"},{"key":"e_1_2_5_49_2","unstructured":"JenkinsJJ SeligmanPJ(US Food and Drug Administration). Memorandum: analysis and recommendations for agency action regarding non\u2010steroidal anti\u2010inflammatory drugs and cardiovascular risk. Center for Drug Evaluation and Research. URL:http:\/\/www.fda.gov\/cder\/drug\/infopage\/COX2\/NSAIDdecisionMemo.pdf."}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.21696","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.21696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T23:37:48Z","timestamp":1697153868000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.21696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,6]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,2,15]]}},"alternative-id":["10.1002\/art.21696"],"URL":"https:\/\/doi.org\/10.1002\/art.21696","archive":["Portico"],"relation":{},"ISSN":["0893-7524","1529-0123"],"issn-type":[{"value":"0893-7524","type":"print"},{"value":"1529-0123","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,6]]}}}